Linus Health to Present Research on Digital Biomarkers for Alzheimer’s and Parkinson’s at AD/PD 2026
BOSTON, March 3, 2026 – Linus Health will present new research at the International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD™ 2026), highlighting the potential of digital cognitive assessments and personalized outcome measures to improve the identification of patients for emerging therapies and the measurement of treatment impact .
Advancements in Digital Cognitive Assessments
The research will be presented at AD/PD™ 2026, taking place March 17-21, 2026, in Copenhagen, Denmark, and online. The conference brings together scientists, clinicians, and industry leaders to discuss the latest advancements in neurodegenerative disease research .
Linus Health will showcase three poster presentations demonstrating the growing role of multimodal digital assessments in accelerating research across Alzheimer’s disease and related disorders.
Key Research Highlights
- Identifying Candidates for Disease-Modifying Therapies: Research demonstrates that combining the Digital Clock and Recall (DCR™) Cognition Score with Amyloid Positivity Risk effectively identifies individuals in early stages of Alzheimer’s disease (mild cognitive impairment or mild dementia) who may benefit from disease-modifying treatments .
- Predicting p-tau217 Status and Alzheimer’s Risk: The Linus Health Digital Assessment of Cognition (DAC) can remotely predict p-tau217 status and provide biologically anchored cognitive phenotyping, aiding in trial prescreening and community screening. The approach shows high accuracy and negative predictive value, potentially reducing unnecessary biomarker testing .
- Personalized Outcome Measures: A feasibility study assesses the applicability and user acceptance of the Electronic Person Specific Outcome Measures (ePSOM) tool in a Japanese memory clinic population. EPSOM captures what matters most to patients and measures their confidence in maintaining those priorities, potentially incorporating individual patient priorities into study endpoints .
Multimodal Approach to Neurodegenerative Research
Linus Health emphasizes its multimodal platform, integrating cognitive, speech, and motor assessments to support research across neurodegenerative conditions, including Alzheimer’s and Parkinson’s disease. This platform helps life sciences organizations identify potential clinical trial participants and develop composite digital endpoints for earlier detection and more precise stratification .
About Linus Health
Linus Health, based in Boston, is a digital health company focused on transforming brain health globally. The company aims to enable longer, healthier lives with better brain health by advancing detection and treatment of cognitive and brain disorders through neuroscience, clinical expertise, and artificial intelligence . Linus Health partners with healthcare organizations, research institutions, and life sciences companies to accelerate proactive intervention and personalized care in brain health. More information can be found at www.linushealth.com or on LinkedIn.